PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
Publication
, Conference
Zhang, T; Ballman, KV; Choudhury, AD; Chen, RC; Watt, C; Wen, Y; Zemla, T; Emamekhoo, H; Vaishampayan, UN; Morris, MJ; George, DJ; Choueiri, TK
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 20, 2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 20, 2020
Volume
38
Issue
6
Location
San Francisco, CA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Ballman, K. V., Choudhury, A. D., Chen, R. C., Watt, C., Wen, Y., … Choueiri, T. K. (2020). PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Tyler Zemla, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38. AMER SOC CLINICAL ONCOLOGY, 2020.
Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, et al. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.
Zhang, Tian, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 6, AMER SOC CLINICAL ONCOLOGY, 2020.
Zhang T, Ballman KV, Choudhury AD, Chen RC, Watt C, Wen Y, Zemla T, Emamekhoo H, Vaishampayan UN, Morris MJ, George DJ, Choueiri TK. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 20, 2020
Volume
38
Issue
6
Location
San Francisco, CA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences